Brandt Esplin, MD
Hematology & Oncology · Provo, UTNPI 1285929430
Payments from drug & device makers
Across 204 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$537
- AstraZeneca$422
- Fennec Pharmaceuticals, Inc.$341
- GSK$281
- Merck$268
- E.r. Squibb & Sons, L.L.C.$232
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$1503%
- Food & beverage$4,12296%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $537 |
| AstraZeneca(2 entities) | 15 | $422 |
| Fennec Pharmaceuticals, Inc. | 1 | $341 |
| GSK | 16 | $281 |
| Merck | 12 | $268 |
| E.r. Squibb & Sons, L.L.C. | 6 | $232 |
| Astellas Pharma US Inc | 11 | $216 |
| Novartis | 9 | $178 |
| AbbVie | 8 | $177 |
| Array Biopharma Inc | 11 | $167 |
| Bristol Myers Squibb | 8 | $160 |
| Sanofi | 7 | $155 |
| Seagen Inc. | 7 | $136 |
| EMD Serono, Inc. | 7 | $127 |
| Gilead | 6 | $123 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $114 |
| Bayer | 4 | $65 |
| Johnson & Johnson | 3 | $58 |
| Geron Corporation | 2 | $52 |
| Incyte Corporation | 3 | $47 |
| Amgen | 2 | $44 |
| Genentech USA, Inc. | 2 | $41 |
| Exelixis Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $30 |
| Sobi, Inc | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Histosonics, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Lilly USA, LLC | 2 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Novocure Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Morphosys, US Inc. | 1 | $16 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Secura Bio, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,315 in reported general payments places this provider in the 35th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 54 | $784,566 |
| Lenalidomide | 60 | $696,789 |
| PomalystPomalidomide | 28 | $519,499 |
| IbrancePalbociclib | 21 | $358,524 |
| KisqaliRibociclib Succinate | 20 | $319,718 |
| InrebicFedratinib Dihydrochloride | 13 | $244,964 |
| NinlaroIxazomib Citrate | 15 | $216,487 |
| ErleadaApalutamide | 14 | $209,028 |
| BraftoviEncorafenib | 13 | $191,863 |
| TagrissoOsimertinib Mesylate | 11 | $190,018 |
| CalquenceAcalabrutinib Maleate | 35 | $139,891 |
| InlytaAxitinib | 14 | $139,827 |
| XtandiEnzalutamide | 11 | $138,523 |
| LynparzaOlaparib | 13 | $110,997 |
| MektoviBinimetinib | 13 | $109,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Inrebic | $160 | $1,029,53067 claims |
| PfizerIbrance, Inlyta, Eliquis | $537 | $536,16878 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $232 | $519,49928 claims |
| AstraZenecaTagrisso, Calquence, Lynparza | $422 | $440,90559 claims |
| NovartisKisqali | $178 | $319,71820 claims |
| Array Biopharma IncBraftovi, Mektovi | $167 | $301,67726 claims |
| Johnson & JohnsonErleada | $58 | $209,02814 claims |
| Astellas Pharma US IncXtandi | $216 | $138,52311 claims |
| AbbVieVenclexta | $177 | $86,16120 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $114 | $37,84115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Provo
- Nathan RichProvo$14K
- Marc NuttallProvo$12K
- Steven WallentineProvo$7K
- Nathan PetersonProvo$3K
- Daniel SimsProvo$2K
- David RirieProvo$1K
- Neeraj AgarwalSalt Lake City$32.4M
- Douglas SborovSalt Lake City$7.8M
- Tsewang TashiSalt Lake City$6.7M
- Benjamin MaughanSalt Lake City$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.